A four-step synthesis of the FDA-approved anticancer agent gefitinib was developed starting from 2,4-dichloro-6,7-dimethoxyquinazoline. Reaction temperatures were highly practical (0–55 °C), and chromatographic purifications were avoided. The ionic liquid trimethylammonium heptachlorodialuminate was used to monodemethylate the dimethoxyquinazoline core. In the final step, a selective dehalogenation
FDA 批准的抗癌剂吉非替尼的四步合成是从 2,4-二氯-6,7-二甲氧基喹唑啉开始的。反应温度非常实用 (0–55 °C),避免了色谱纯化。离子液体三甲基铵七氯二铝酸盐用于单去甲基化二甲氧基喹唑啉核。在最后一步中,采用选择性脱卤以提供 14% 克级总收率的吉非替尼。